ABUS

Arbutus Biopharma Corp (ABUS) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection. The company's primary pipeline assets are imdusiran (an RNAi therapeutic in Phase 2a trials) and AB-101 (an oral PD-L1 inhibitor in Phase 1a/1b trials). The company is also engaged in significant intellectual property litigation regarding its lipid nanoparticle (LNP) technology against Moderna and Pfizer/BioNTech.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 71% in Q3 and 72% in the first nine months of 2024 compared to 2023. This was driven by a significant reduction in license revenue from the Qilu Pharmaceutical agreement (as performance obligations were satisfied) and lower royalty revenue from Alnylam's ONPATTRO sales.
• Restructuring Charge: The company incurred a one-time $3.6 million restructuring charge in Q3 2024. This included $2.9 million in cash severance, $0.2 million in equipment impairment, and $0.5 million in vendor close-out costs. This followed a 40% workforce reduction and the cessation of all discovery efforts and the IM-PROVE III clinical trial to focus resources on imdusiran and AB-101.
• Operating Expense Reduction: Despite the restructuring charge, total operating expenses decreased year-over-year due to the discontinuation of non-core programs (coronavirus and AB-161) and headcount reductions.
• Capital Raise: The company raised approximately $44.1 million in net proceeds during the first nine months of 2024 through its Open Market Sale Agreement (ATM), compared to $26.0 million in the same period in 2023.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects current cash resources ($130.8 million) to fund operations into the fourth quarter of 2026. The company anticipates a net cash burn between $63 million and $67 million for the full year 2024.
• Clinical Milestones:
  • IM-PROVE I & II: Data from these Phase 2a trials combining imdusiran with other agents is expected to be presented at the AASLD - The Liver Meeting in November 2024.
  • AB-101: Preliminary data from the Phase 1a/1b trial is expected in the first half of 2025.
• Litigation Status:
  • Moderna: The trial start date was moved from April 2025 to September 24, 2025.
  • Pfizer/BioNTech: A claim construction hearing is scheduled for December 18, 2024.
  • Acuitas: The declaratory judgment lawsuit was dismissed by the court in May 2024.
• Risks: Success depends on regulatory approvals, clinical trial outcomes, and the ability to secure additional financing. The company has no outstanding debt but relies on equity financing and royalty streams.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of the $130.8 million cash position against the projected $63-67 million annual burn rate and potential delays in clinical data readouts.
• Revenue Visibility: Assess the impact of the declining Qilu license revenue and the uncertainty of future royalty payments from ONPATTRO sales.
• Litigation Timelines: Monitor the rescheduled trial date for the Moderna lawsuit (Sept 2025) and the upcoming claim construction hearing for Pfizer/BioNTech (Dec 2024) for potential financial upside or legal costs.
• Restructuring Impact: Confirm that the 40% workforce reduction and cessation of discovery programs effectively lower the long-term operating cost base as intended.
• ATM Capacity: Note that approximately $25.4 million remains available under the current Open Market Sale Agreement, which may limit immediate capital raising options without a new shelf registration.